Albuminuria Reduction Accounts for Much of Finerenone Effect on CKD

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

MONDAY, Dec. 4, 2023 -- For patients with chronic kidney disease (CKD) and type 2 diabetes, early albuminuria reduction accounts for a large proportion of the treatment effect of finerenone against CKD progression, according to a study published online Dec. 5 in the Annals of Internal Medicine.

Rajiv Agarwal, M.D., from Indiana University in Indianapolis, and colleagues quantified the proportion of kidney and cardiovascular risk reductions seen during a four-year period mediated by a change in kidney injury in a post-hoc analysis using pooled data from two phase 3 trials of finerenone. Data were included for 12,512 patients with CKD and type 2 diabetes who received finerenone and placebo (1:1 ratio).

The researchers found that the median urine albumin-to-creatinine ratio (UACR) was 514 mg/g at baseline. Overall, 53.2 and 27.0 percent of patients in the finerenone and placebo groups, respectively, had a 30 percent or greater reduction in UACR. Eighty-four and 37 percent of the treatment effect on the kidney and cardiovascular outcomes, respectively, was mediated by a reduction in UACR (analyzed as a continuous variable). The corresponding proportions mediated were 64 and 26 percent when change in UACR was assessed as a binary variable (whether the 30 percent reduction threshold was met).

"The current results emphasize the importance of monitoring UACR after initiating treatment, as it can serve as a valuable surrogate indicator of the early treatment efficacy and offer insights into potential long-term kidney and cardiovascular benefits," the authors write.

The study was funded by Bayer, the manufacturer of finerenone.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-12-05 06:36

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords